CTS Corporation (CTS) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call showed positive financial performance with improved EBITDA and gross margin, strong aerospace and medical sales, and shareholder returns. Despite transportation sales decline, guidance remains optimistic. Analysts' Q&A highlighted growth in therapeutics and potential recovery in transportation. The integration of SyQwest and operational efficiency are progressing well. Overall, the positive financial metrics and optimistic guidance suggest a likely stock price increase in the near term.
Key Financial Performance
Sales $135 million, up 4% from $130 million in the second quarter of 2024. Diversified end market sales increased 13% year-over-year, driven by organic growth and the SyQwest acquisition. Transportation sales were down 6% due to China market dynamics and softness in commercial vehicle products.
Adjusted EBITDA 23% in the quarter, an improvement of 250 basis points sequentially and 130 basis points compared to the second quarter of 2024. This was due to favorable mix impact and operational execution.
Adjusted Gross Margin 38.7% in the second quarter, up 296 basis points compared to the second quarter of 2024 and up 174 basis points sequentially. Favorable mix impact and operational execution contributed to this improvement.
Adjusted Diluted Earnings $0.57 per share, up approximately 30% from the first quarter of 2025 and up 7% from the prior year period.
Operating Cash Flow $28 million in the second quarter, compared to $20 million in the second quarter of 2024, driven by strong cash generation.
Aerospace and Defense Sales Up 34% from the second quarter of 2024. Excluding SyQwest acquisition, sales were up 6%. SyQwest contributed $4.5 million in revenue.
Medical End Market Sales Up 8% compared to the same period in 2024. Demand for therapeutic products increased approximately 60% year-over-year, while bookings were down 10% due to softness in diagnostic bookings.
Industrial Market Sales Up 6% compared to the prior year period. Bookings increased 22% year-over-year, reflecting a gradual recovery.
Transportation Sales $61 million in the second quarter, down approximately 6% from the same period last year due to China market dynamics and softness in commercial vehicle products.
Shareholder Returns $26 million returned to shareholders through dividends and share buybacks in 2025, including $17 million for 412,000 shares repurchased in the second quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Next-generation smart actuator: Launched for the commercial vehicle market.
Medical ultrasound products: Wins across all regions and an award for a pacemaker application. Added a new customer for an ultrasound application.
Corvus technology: Advanced technology enabling precise position sensing for motor position sensing.
Diversified end markets: Sales up 13% year-over-year, driven by organic growth and SyQwest acquisition. Medical, aerospace, defense, and industrial markets contributed significantly.
Aerospace and Defense: Sales up 34% year-over-year, with SyQwest contributing $4.5 million. Multiple orders for sonar transducers and other applications.
Industrial market: Sales up 6% year-over-year. New business awards for EV charging stations in Europe and millimeter wave small cell frequency applications.
Adjusted EBITDA: Improved by 250 basis points sequentially and 130 basis points year-over-year.
Cash flow generation: Generated $28 million in operating cash flow in Q2 2025, up from $20 million in Q2 2024.
Gross margin: Adjusted gross margin improved to 38.7%, up 296 basis points year-over-year.
Diversification strategy: Focused on increasing growth in medical, industrial, aerospace, and defense markets. Transitioning from component supplier to subsystem supplier in Aerospace and Defense.
SyQwest acquisition: Integration progressing well, contributing to revenue growth and a strong pipeline of opportunities.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Transportation Sales: Sales were down 6% from the same period last year due to impacts of China market dynamics and softness for commercial vehicle products. Additionally, production volumes are expected to decrease in 2025 due to tariff impacts and rare earth supply issues for OEMs and Tier 1 suppliers.
Medical End Market: Bookings in the quarter were down 10% compared to the prior year period due to softness in diagnostic bookings. Demand in the medical end market is expected to be mixed, with strength in therapeutics but some softness in diagnostic ultrasound.
Aerospace and Defense: Revenue from the SyQwest acquisition introduces seasonality, with timing influenced by U.S. government funding approvals. Geopolitical and tariff impacts are creating uncertainty.
Industrial Market: Gradual recovery is observed, but demand is subject to evolving trade tariffs and associated economic uncertainty.
Electric Vehicle (EV) Market: Electric vehicle penetration rates have softened in some regions, while hybrid adoption improves. Interest in e-brake products is slower as OEMs recalibrate EV investments.
Geopolitical and Tariff Impacts: Tariffs and geopolitical environment are creating uncertainty, impacting transportation revenue and overall market dynamics.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: CTS Corporation is maintaining its guidance of sales in the range of $520 million to $550 million for 2025.
Earnings Per Share (EPS) Guidance: Adjusted diluted EPS is expected to be in the range of $2.20 to $2.35 for 2025.
Medical End Market Outlook: Demand in the medical end market is expected to be mixed, with strength in therapeutics and some softness in diagnostic ultrasound. Volume increases in portable ultrasound diagnostics and therapeutics are expected to enhance growth over time.
Aerospace and Defense Outlook: Revenue is expected to grow due to a healthy backlog of orders and momentum from the SyQwest acquisition. SyQwest revenues are anticipated to improve in the second half of 2025.
Industrial Market Outlook: Sales are expected to improve in the second half of 2025, supported by megatrends of automation, connectivity, and efficiency.
Transportation Market Outlook: Production volumes are expected to decrease in 2025 due to tariff impacts and rare earth supply issues. North American light vehicle market is expected to be around 15 million units, European production at 16 million units, and China volumes at 30 million units. Electric vehicle penetration rates have softened in some regions, while hybrid adoption continues to improve. Commercial vehicle-related revenue is anticipated to remain soft for the remainder of the year.
SyQwest Revenue Seasonality: Revenues from the SyQwest acquisition are expected to improve in the second half of 2025, influenced by U.S. government funding approvals.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: In total, we returned $26 million to shareholders through dividends and share buybacks so far in 2025.
Share Repurchase: During the quarter, we repurchased 412,000 shares of CTS stock for approximately $17 million. We have $38 million remaining under our current share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the performance of the medical market, particularly the differences between therapeutics and diagnostics?
A:Therapeutics saw a 60% increase, driven by a larger order discussed in the last earnings call. Diagnostics experienced softness, particularly in ultrasound, due to reduced capital spending in Asia and potential tariff impacts. Overall, the medical market is expected to grow this year.
Q:What was the impact of tariffs on the company during the quarter?
A:The impact of tariffs was minimal. The company is working closely with customers and suppliers and is monitoring the situation, especially potential changes in the USMCA.
Q:When might the transportation market bottom out?
A:The transportation market shows mixed performance. Weakness persists, particularly in China, but there are signs of bottoming out. Light vehicle performance improved sequentially, and the company has a strong pipeline of booked business. However, the situation remains tenuous for the next few quarters.
Q:How is the integration of SyQwest progressing, and are there any cost-saving measures being implemented?
A:The SyQwest integration is progressing well, with most work completed except for ERP system integration. The focus is on growth rather than cost-saving measures. For legacy CTS, operational efficiency improvements are ongoing, contributing to gross margin expansion, but no major public initiatives are currently underway.
Q:Can you provide more details on the mix dynamics in the medical marketplace and the outlook for diagnostics and therapeutics?
A:Softness in diagnostics may persist for a quarter or two, but long-term growth is expected. Therapeutics is expected to grow throughout the year, with new purchase orders anticipated. Overall, the medical market is expected to grow this year and in the future.
Q:How much revenue did SyQwest generate in the same quarter a year ago?
A:The company did not disclose pre-acquisition revenue figures for SyQwest.
Q:What percentage of transportation revenue comes from China?
A:China's transportation revenue is proportional to the overall transportation revenue as a percentage of total CTS revenue. Last year's total revenue from China was about $80 million.
Q:What are the key products in the transportation pipeline, and which regions are they focused on?
A:Key products include accelerator modules, passive safety sensors, new combination sensors, and motor position sensing. The pipeline is strongest in North America but includes global opportunities with OEMs.
Q:What is the company's focus in the acquisition market, and are there any expected developments?
A:The focus is on advancing diversified end markets such as aerospace, defense, industrial, and medical. While there is no specific news, the company aims to achieve 5% growth through acquisitions within the next 12 months.
Q:Review of Unclear Management Responses
A:Management avoided providing specific pre-acquisition revenue figures for SyQwest and used vague language regarding potential changes in the transportation market and tariff impacts. Additionally, no detailed cost-saving measures for legacy CTS were disclosed.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aerospace Defense
America Europe
Bookings period
Chairman President
China market
EV
LLC
North America
OEMs Tier
SyQwest acquisition
actuator
application Demand
approval
award
booking
brake
cost
customer
dynamic softness
generation
line
position
production
prospect
revenue
sale SyQwest
supplier
tariff
team
technology
term
transducer
ultrasound
unit
vehicle
volume
CTS Transcript
CTS Corporation (CTS) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call highlights double-digit sales growth due to effective diversification, particularly in industrial and medical markets, with stable transportation revenue. Despite potential risks, the strong operational execution and strategic positioning suggest positive sentiment. The absence of clear concerns in the Q&A further supports this outlook. However, no shareholder return plans were discussed, keeping the sentiment from being 'strong positive.'
CTS Corporation (CTS) Q4 2025 Earnings Call Transcript
Positive2-10
The earnings call summary indicates strong financial performance with increased sales in key markets like Medical and Industrial. Despite a decline in Transportation, new business awards and operational efficiencies improved EBITDA margins. The Q&A session highlighted strong demand and product development, though some management responses lacked clarity. Overall, the positive sales growth, improved margins, and strategic advancements in diversified markets suggest a positive stock price movement in the short term.
CTS Corporation (CTS) Q3 2025 Earnings Call Transcript
Unknown10-28
The earnings call reflects mixed signals: while aerospace, defense, industrial, and medical markets show strong performance, the transportation sector struggles, and EPS guidance was lowered due to tax impacts. Positive aspects include strong market growth and the SyQwest acquisition meeting expectations, but the adverse tax impact and transportation market softness temper enthusiasm. The Q&A session highlighted some concerns, such as unclear management responses and ongoing tax issues. Given the balance of positive and negative factors, the stock price is likely to remain stable over the next two weeks.
CTS Corporation (CTS) Q2 2025 Earnings Call Transcript
Positive7-24
The earnings call showed positive financial performance with improved EBITDA and gross margin, strong aerospace and medical sales, and shareholder returns. Despite transportation sales decline, guidance remains optimistic. Analysts' Q&A highlighted growth in therapeutics and potential recovery in transportation. The integration of SyQwest and operational efficiency are progressing well. Overall, the positive financial metrics and optimistic guidance suggest a likely stock price increase in the near term.
CTS Slides
CTS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
